Abstract

A once-daily, 10-mg oral dose of rivaroxaban was significantly more effective for extended thromboprophylaxis than a once-daily, 40-mg subcutaneous dose of enoxaparin in patients undergoing elective total hip arthroplasty. The two drugs had similar safety profiles. (ClinicalTrials.gov number, NCT00329628.)

Keywords

MedicineRivaroxabanPulmonary embolismDeep veinSurgeryVenographyEnoxaparin sodiumThrombosisVenous thrombosisPlaceboAnesthesiaLow molecular weight heparinInternal medicineWarfarinAtrial fibrillation

Affiliated Institutions

Related Publications

Publication Info

Year
2008
Type
article
Volume
358
Issue
26
Pages
2765-2775
Citations
1419
Access
Closed

External Links

View on DOI.org

Social Impact

Altmetric
PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1419
OpenAlex

Cite This

Bengt I. Eriksson, Lars C. Borris, Richard J. Friedman et al. (2008). Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty. New England Journal of Medicine , 358 (26) , 2765-2775. https://doi.org/10.1056/nejmoa0800374

Identifiers

DOI
10.1056/nejmoa0800374